Business
Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON Safety Trial Data Presented at 2025 Society of Vascular and Interventional Neurology Annual Meeting Company Continues Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA Submission for GTx-104 for the Treatment of Patients with aSAH PRINCETON, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE
About this update from Grace Therapeutics, Inc.
[{"type":"image","alt":"Grace Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Grace Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":238,"height":52,"url":"https://media.zenfs.com/en/globenewswire.com/d9c2bb0e1d56296ef30bd84c47a14138"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Sz8Ci7mRHoF.VDufghVM3w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/d9c2bb0e1d56296ef30bd84c47a14138","width":238,"height":52}},"lazy":false},{"type":"text","content":"FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)","length":181,"tagName":"p"},{"type":"text","content":"Phase 3 STRIVE-ON Safety Trial Data Presented at 2025 Society of Vascular and Interventional Neurology Annual Meeting","length":117,"tagName":"p"},{"type":"text","content":"Company Continues Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA Submission for GTx-104 for the Treatment of Patients with aSAH","length":153,"tagName":"p"},{"type":"text","content":"PRINCETON, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the quarter ended December 31, 2025.","length":436,"tagName":"p"},{"type":"text","content":"“During our third quarter of fiscal 2026 we continued to execute on our clinical and corporate goals, led by our pre-commercial planning in anticipation of potential FDA approval of our New Drug Application (NDA) for GTx-104 for the treatment of aSAH,” said Prashant Kohli, CEO of Grace Therapeutics. “Our NDA is supported by a robust data package, including positive results from our STRIVE-ON trial, which provided evidence of improved clinical outcomes in aSAH patients treated with GTx-104 as well as potential medical and pharmacoeconomic benefits of GTx-104 in the treatment of aSAH. We were pleased to see these data highlighted in a late breaking presentation at the Society of Vascular and Interventional Neurolo...